Innovent Biologics Stock Beta
| IVBXF Stock | USD 4.85 0.24 4.72% |
Innovent Biologics fundamentals help investors to digest information that contributes to Innovent Biologics' financial success or failures. It also enables traders to predict the movement of Innovent Pink Sheet. The fundamental analysis module provides a way to measure Innovent Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innovent Biologics pink sheet.
Innovent |
Innovent Biologics Company Beta Analysis
Innovent Biologics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Innovent Biologics Beta | 0.16 |
Most of Innovent Biologics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovent Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Innovent Biologics has a Beta of 0.1642. This is 80.91% lower than that of the Healthcare sector and 88.19% lower than that of the Biotechnology industry. The beta for all United States stocks is notably lower than that of the firm.
Innovent Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innovent Biologics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Innovent Biologics could also be used in its relative valuation, which is a method of valuing Innovent Biologics by comparing valuation metrics of similar companies.Innovent Biologics is currently under evaluation in beta category among its peers.
As returns on the market increase, Innovent Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Innovent Biologics is expected to be smaller as well.
Innovent Fundamentals
| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.68) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 5.13 B | |||
| Shares Outstanding | 1.53 B | |||
| Shares Owned By Insiders | 7.15 % | |||
| Shares Owned By Institutions | 44.34 % | |||
| Price To Book | 4.22 X | |||
| Price To Sales | 1.39 X | |||
| Revenue | 4.27 B | |||
| Gross Profit | 2.98 B | |||
| EBITDA | (2.99 B) | |||
| Net Income | (3.14 B) | |||
| Cash And Equivalents | 8.32 B | |||
| Cash Per Share | 5.67 X | |||
| Total Debt | 2.02 B | |||
| Debt To Equity | 0.29 % | |||
| Current Ratio | 3.21 X | |||
| Book Value Per Share | 6.54 X | |||
| Cash Flow From Operations | (2.02 B) | |||
| Earnings Per Share | (0.32) X | |||
| Number Of Employees | 5.54 K | |||
| Beta | 0.16 | |||
| Market Capitalization | 8.37 B | |||
| Total Asset | 16.24 B | |||
| Z Score | 2.4 | |||
| Net Asset | 16.24 B |
About Innovent Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innovent Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innovent Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innovent Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.